1. Ahmed NZ, Agibothu Kupparam HK, Akbar S, Hissar S, Anwar N, Thiruvengadam K, et al. Effects of co-administration of Unani pharmacopoeia formulations Qurs Tabasheer Sartani and Arq Hara Bhara with CAT-I antitubercular drugs in rats. Journal of complementary & integrative medicine. 2021; May (IF: Nil) ).

2.  Aishwarya V, Kumar NP, Hanna LE, Putlibai S, Karthick M, Rajamanikam A, et al. Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children - a cross-sectional observational study from southern India. EBioMedicine. 2021;66:103317.

3. Anuradha R, Kumar NP, Padmapriyadarsini C, Nancy A, Selvaraj N, Karunanithi K, et al. Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection. The Journal of infection. 2021;83(3):339-46 (IF: 6.072) .

4.  Banurekha V, Jawahar MS, Padmapriyadarsini C. Authors' Response to 'False equivalence of four month and six-month ATT regimen: a case of comparing apples and oranges'. Tropical medicine & international health : TM & IH. 2021;26(5):608.

5.  Chakma T, Thomas BE, Kohli S, Moral R, Menon GR, Periyasamy M, et al. Psychosocial impact of COVID-19 pandemic on healthcare workers in India & their perceptions on the way forward - A qualitative study. Indian J Med Res. 2021;153(5&6):637-48.

6.  Christe DM, Thiripurasundari G, Alfonso T. Efficacy of VIA, VILI, PAP Smear, and FRD Tests in Screening for Cervical Cancer: A Comparative Study. Indian Journal of Gynecologic Oncology. 2021;19 (IF: Nil) ).

7.  Christie DM, Padmanaban S. Respectful Maternity Care Initiative: A Qualitative Study. The Journal of Obstetrics and Gynaecology of India. 2021(April): (IF: Nil) .

8.  Cox SR, Gupte AN, Thomas B, Gaikwad S, Mave V, Padmapriyadarsini C, et al. Unhealthy alcohol use independently associated with unfavorable TB treatment outcomes among Indian men. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2021;25(3):182-90.

9.  Divya P, Bahi M, Padmapriyadarshini C, Kumar R, Semwal S, Labroo SR, et al. Clinical data monitoring during COVID-19 pandemic: an experience from a regulatory trial in India. International Journal of Clinical Trials. 2021;8(2):163-6 (IF: Nil)

10.  Dolla CK, Padma Priyadarshini C, Bhavani PK, Kannan T, Kumaravel P, Devika K. Roaming homeless persons, India-Pulmonary tuberculosis. The Indian journal of tuberculosis. 2021;68(2):279-80 (IF: Nil) .

11.  Dusthackeer A, Kumar A, Mohanvel SK, Mahizhaveni B, Shivakumar S, Raghavi S, et al. Mycobacterium tuberculosis strain lineage in mixed tribal population across India and Andaman Nicobar Island. World J Microbiol Biotechnol. 2021;37(11):192.

12.  Dusthackeer A, Saadhali SA, Thangam M, Hassan S, Balasubramanian M, Balasubramanian A, et al. Wild-Type MIC Distribution for Re-valuating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India. Frontiers in microbiology. 2020;11:1182 (IF: 5.64) .

13.  Gopalan N, Srinivasalu VA, Chinnayan P, Velayutham B, Bhaskar A, Santhanakrishnan R, et al. Predictors of unfavorable responses to therapy in rifampicin-sensitive pulmonary tuberculosis using an integrated approach of radiological presentation and sputum mycobacterial burden. PloS one. 2021;16(9):e0257647 (IF: 3.24) .

14.  Gopalaswamy. R, N. ADV, Kannayan. S, Subbian. S. Extrapulmonary Tuberculosis—An Update on the Diagnosis, Treatment and Drug Resistance. Journal of Respiration. 2021;1:141–64.

15.  Gupte AN, Selvaraju S, Gaikwad S, Mave V, Kumar P, Babu S, et al. Higher interleukin-6 levels and changes in transforming growth factor-ß are associated with lung impairment in pulmonary tuberculosis. ERJ open research. 2021;7(1).

16.  Harini R, Thiruvengadam K, Singaraj R, Palaniyandi K. Role of abattoir monitoring in determining the prevalence of bovine tuberculosis: A systematic review and meta-analysis. Transboundary and emerging diseases. 2021: Apr. (IF: 5.005) .

17.  Harishankar M, Sampath P, Sriram M, Raghuraman R, Athikesavan V, Chinnaiyan P, et al. Association of CYP2R1 gene polymorphisms in pulmonary tuberculosis. Meta Gene. 2021;28(June):100875 (IF: Nil) .

18.  Hemanth Kumar A, K., Sudha A, Vijayakumar C, Padmapriyadarshini C. Simultaneous method for the estimation of Bedaquiline and delamanid in human plasma using high-performance liquid chromatography. International Journal of Pharmacy and Pharmaceutical Sciences. 2021 13(6):36-40 (IF: Nil) .

19.  Jeyakumar SM. Micronutrient Deficiency in Pulmonary Tuberculosis - Perspective on Hepatic Drug Metabolism and Pharmacokinetic Variability of First-line Anti- Tuberculosis Drugs: Special Reference to Fat-soluble Vitamins A, D, & E and Nutri-epigenetics. Drug Metab Lett. 2021;14(3):166-76.

20.  Jeyakumar SM, Vajreswari A. Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non- alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. World Journal of Clinical Cases. 2021;9(31):9333-49.

21.  Kathamuthu GR, Kumar NP, Moideen K, Menon PA, Babu S. Decreased Frequencies of Gamma/Delta T Cells Expressing Th1/Th17 Cytokine, Cytotoxic, and Immune Markers in Latent Tuberculosis-Diabetes/Pre-Diabetes Comorbidity. Frontiers in cellular and infection microbiology. 2021;11:756854.

22.  Kathamuthu GR, Kumar NP, Sridhar R, Baskaran D, Babu S. Ex-vivo immunophenotyping and high dimensionality UMAP analysis of leucocyte subsets in tuberculous lymphadenitis. Tuberculosis (Edinb). 2021;130:102117.

23.  Kathamuthu GR, Moideen K, Sridhar R, Baskaran D, Babu S. Altered plasma levels of ßC and ?C chain cytokines and post-treatment modulation in tuberculous lymphadenitis. Cytokine. 2021;138:155405 (IF: 3.861) .

24.  Kathamuthu GR, Moideen K, Sridhar R, Baskaran D, Babu S. Reduced neutrophil granular proteins and post-treatment modulation in tuberculous lymphadenitis. PloS one. 2021;16(6):e0253534 (IF: 3.24) .

25.  Kathamuthu GR, Moideen K, Sridhar R, Baskaran D, Babu S. Plasma adipocytokines distinguish tuberculous lymphadenitis from pulmonary tuberculosis. Tuberculosis (Edinb). 2021;132:102161.

26.  Kaur G, Chauhan AS, Prinja S, Teerawattananon Y, Muniyandi M, Rastogi A, et al.

Cost-effectiveness of population-based screening for diabetes and hypertension in India: an economic modelling study. The Lancet Public health. 2021: Nov (IF: Nil) .

27.  Kaur P, Potluri V, Ahuja VK, Naveenkumar CN, Krishnamurthy RV, Gangadharaiah ST, et al. A multi-targeting pre-clinical candidate against drug-resistant tuberculosis. Tuberculosis (Edinb). 2021;129:102104 (IF: 3.131) .

28.  Kumar NP, Banurekha VV, C PG, Nancy A, Padmapriyadarsini C, Mary AS, et al. Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses. Front Immunol. 2021;12:752397.

29.  Kumar NP, Hissar S, Thiruvengadam K, Banurekha VV, Balaji S, Elilarasi S, et al. Plasma chemokines as immune biomarkers for diagnosis of pediatric tuberculosis. BMC infectious diseases. 2021;21(1):1055.

30.  Kumar NP, Venkataraman A, Hanna LE, Putlibai S, Karthick M, Rajamanikam A, et al. Systemic Inflammation and Microbial Translocation Are Characteristic Features of SARS-CoV-2-Related Multisystem Inflammatory Syndrome in Children. Open Forum Infect Dis. 2021;8(7):ofab279.

31.  Kumar S, Shrinivasa B, Hissar S, Rajasakthivel M. Ethical implications of the National Tuberculosis Elimination Programme in India: A framework-based analysis. International Journal of Health & Allied Sciences. 2021;10(4):253-6.

32.  Kumar. RS, Devi. KRU, Dusthackeer. A, Nirmal. CR. Ofloxacin resistance in Mycobacterium tuberculosis: An increasing concern. INDIAN Journal of Health Sciences and Biomedical Research KLEU. 2021; Sep

33.  Lipman M, McQuaid CF, Abubakar I, Khan M, Kranzer K, McHugh TD, et al. The impact of COVID-19 on global tuberculosis control. The Indian journal of medical research. 2021;153(4):404.

34.  Muniyandi M, Karikalan N, Ravi K, Sengodan S, Krishnan R, Tyagi K, et al. An economic evaluation of implementing a decentralized dengue screening intervention under the National Vector Borne Disease Control Programme in Tamil Nadu, South India. International health. 2021: Aug (IF: 2.473) .

35. Muniyandi M, Nagarajan K, Kirti T, Malkeet S, Venkatesan P, SenthilKumar S, et al. Economic Evaluation of Implementing a Rapid Point-of-Care Screening Test for the Identification of epatitis C Virus under National Viral Hepatitis Control Programme in Tamil Nadu, South India. Journal of Global Infectious Diseases. 2021;13(3): (IF: Nil) .

36. Muniyandi M, Singh M, Singh M, Rajshekhar K, Katoch K. Cost-effectiveness of incorporating Mycobacterium indicus pranii vaccine to multidrug therapy in newly diagnosed leprosy cases for better treatment outcomes & immunoprophylaxis in contacts as leprosy control measures for National Leprosy Eradication Programme in India. Indian J Med Res. 2021;154(1):121-31 (IF: 2.375) .

37.  Nagarajan K, Muniyandi M, Palani B, Sellappan S. Tracing the potential extra-household contacts of TB patients: findings from a personal social network survey in a high TB burden setting in India. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2021: July (IF: 2.184) .

38.  Padmapriyadarsini C, Sachdeva KS, Nair D, Ramachandran R. The paradigm shift in the approach to management of latent tuberculosis infection in high tuberculosis burden countries. Expert review of respiratory medicine. 2021:1-12.

39.  Pavankumar N, Hissar S, Thiruvengadam K, Banurekha VV, Suresh N, Shankar J, et al. Discovery and Validation of a Three-Cytokine Plasma Signature as a Biomarker for Diagnosis of Pediatric Tuberculosis. Front Immunol. 2021;12:653898 (IF: 7.561) .

40.  PavanKumar N, Moideen K, Nancy A, Viswanathan V, Thiruvengadam K, Sivakumar S, et al. Acute Phase Proteins Are Baseline Predictors of Tuberculosis Treatment Failure. Frontiers in Immunology. 2021;12(4739): (IF: 7.561) .

41.  Pavankumar N, Moideen K, Viswanathan V, Sivakumar S, Hissar S, Kornfeld H, et al. Effect of anti-tuberculosis treatment on the systemic levels of tissue inhibitors of metalloproteinases in tuberculosis - Diabetes co-morbidity. Journal of clinical tuberculosis and other mycobacterial diseases. 2021;23:100237 (IF: Nil) .

42.  PavanKumar N, Padmapriyadarsini C, Rajamanickam A, Bhavani PK, Nancy A, Jayadeepa B, et al. BCG vaccination induces enhanced frequencies of memory T cells and altered plasma levels of common ?c cytokines in elderly individuals. PloS one. 2021;16(11):e0258743 (IF: 3.24) .

43.  PavanKumar N, Padmapriyadarsini C, Rajamanickam A, Bhavani PK, Nancy A, Jeyadeepa B, et al. BCG vaccination induces enhanced frequencies of dendritic cells and altered plasma levels of type I and type III interferons in elderly individuals. Int J Infect Dis. 2021;110:98-104 (IF: 3.623) .

44.  PavanKumar N, Padmapriyadarsini C, Rajamanickam A, Marinaik SB, Nancy A, Padmanaban S, et al. Effect of BCG vaccination on proinflammatory responses in elderly individuals. Science Advances. 2021;7(32): (IF: 14.136)

45.  Pavankumar N, Padmapriyadarsini C, Uma Devi KR, Banurekha VV, Nancy A, Girish Kumar CP, et al. Antibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study. Indian J Med Res. 2021: Sep (IF: 2.375) .

46.  Pavithra S, Periyasamy KM, Ranganathan UD, and, Bethunaickan R. Monocyte and Macrophage miRNA: Potent Biomarker and Target for Host-Directed Therapy for Tuberculosis. Frontiers in Immunology. 2021;12 (IF: 7.561) .

47.  Peraman R, Sure SK, Dusthackeer VNA, Chilamakuru NB, Yiragamreddy PR, Pokuri C, et al. Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance. Future journal of pharmaceutical sciences. 2021;7(1):56 (IF: Nil) .

48.  Peraman R, Sure SK, Dusthackeer VNA, Chilamakuru NB, Yiragamreddy PR, Pokuri C, et al. Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance. Future journal of pharmaceutical sciences. 2021;7(1):56.

49.  Radha G, Padmapriyadarsini C, Sekar K, Vijayaragavan V, Bhavani PK, Lokanathan LM, et al. Pulmonary Mycobacterium abscessus and response to treatment in an outpatient setting: Case series. International journal of mycobacteriology. 2021;10(1):93-7.

50.  Rajamanickam A, Kumar NP, Nancy PA, Selvaraj N, Munisankar S, Renji RM, et al. Recovery of Memory B-cell Subsets and Persistence of Antibodies in Convalescent COVID-19 Patients. Am J Trop Med Hyg. 2021;105(5):1255-60.

51.  Rajamanickam A, Kumar NP, Padmapriyadarsini C, Nancy A, Selvaraj N, Karunanithi K, et al. Latent tuberculosis co-infection is associated with heightened levels of humoral, cytokine and acute phase responses in seropositive SARS-CoV-2 infection. The Journal of infection. 2021;83(3):339-46.

52.  Rajamanickam A, Kumar NP, Pandiarajan AN, Selvaraj N, Munisankar S, Renji RM, et al. Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals. Scientific reports. 2021;11(1):20254.

53.  Rajamanickam A, Munisankar S, Menon PA, Nutman TB, Babu S. Diminished Circulating Levels of Angiogenic Factors and Rage Ligands in Helminth-Diabetes Comorbidity and Reversal Following Anthelmintic Treatment. The Journal of infectious diseases. 2021;224(9):1614-22.

54.  Ramesh S, Kumar KR, Uma Devi KR, Dusthackeer A, Nirmal CR. Ofloxacin resistance in Mycobacterium tuberculosis: An increasing concern. INDIAN Journal of Health Sciences and Biomedical Research KLEU. 2021;14(3) Sep-Dec (IF: Nil) .

55.  Rao VG, Muniyandi M, Sharma RK, Yadav R, Bhat J. Long-term survival of patients treated for tuberculosis: a population-based longitudinal study in a resource-poor setting. Tropical medicine & international health : TM & IH. 2021;26(9):1110-6 (IF: 2.622) .

56.  Rebecca YM, Sudha Y, Viyayakumar A, Hemanth Kumar A, K. Quantitation of Metformin in Urine By Rp-Hplc Method and its Application in Pharmacokinetics. International Journal of Pharmacy and Pharmaceutical Sciences. 2021;13(5): (IF: Nil) .

57.  Rukmini S, Sudhir PM, Bhaskar A, Arumugham SS. Identifying mediators of cognitive behaviour therapy and exposure therapy for social anxiety disorder (SAD) using repeated measures. Journal of Affective Disorders Reports. 2021;6:100194 (IF: Nil) .

58.  Safren SA, Devaleenal B, Biello KB, Rawat S, Thomas BE, Regenauer KS, et al. Geographic and behavioral differences associated with sexually transmitted infection prevalence among Indian men who have sex with men in Chennai and Mumbai. Int J STD AIDS.956462420943016.

59.  Saravanan P, Dusthackeer VNA, Rajmani RS, Mahizhaveni B, Nirmal CR, Rajadas SE, et al. Discovery of a highly potent novel rifampicin analog by preparing a hybrid of the precursors of the antibiotic drugs rifampicin and clofazimine. Scientific reports.11(1):1029.

60.  Saravanan P, Dusthackeer VNA, Rajmani RS, Mahizhaveni B, Nirmal CR, Rajadas SE, et al. Discovery of a highly potent novel rifampicin analog by preparing a hybrid of the precursors of the antibiotic drugs rifampicin and clofazimine. Scientific reports. 2021;11(1):1029 (IF: 4.379) .

61.  Srinivasan R, Padmapriyadarsini C, Ramesh K, Sanjeeva GN, Reddy D, Suresh E, et al. APOC3 Gene Polymorphism and Antiretroviral Therapy-Induced Dyslipidemia in HIV-Infected Children. AIDS research and human retroviruses. 2021;37(2):92-100.

62.  Sriram S, Thiruvengadam K, Watson B, Thirumalai N, Malaisamy M, Vedachalam C, et al. Long-term Survival of Treated Tuberculosis Patients in Comparison to a General Population In South India: A Matched Cohort Study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;110:385-93 (IF: 3.623) .

63.  Subhashni B, Inbakandan D, Thirugnanasambandam R, Kumar C, Sampath P, Bethunaickan R, et al. A comparative study on chitosan nanoparticle synthesis methodologies for application in aquaculture through toxicity studies. IET Nanobiotechnology. 2021;15:418-26 (IF: 1.859) .

64.  Tamilzhalagan S, Shanmugam. S, Selvaraj. A, Suba. S, Suganthi. C, Moonan. PK, et al. Whole-Genome Sequencing to Identify Missed Rifampicin and Isoniazid Resistance Among Tuberculosis Isolates—Chennai, India, 2013–2016. Frontiers in microbiology. 2021;12(22 November): (IF: 5.64) .

65.  Thomas BE, Thiruvengadam K, Vedhachalam C, A S, Rao VG, Vijayachari P, et al. Prevalence of pulmonary tuberculosis among the tribal populations in India. PloS one. 2021;16(6):e0251519.

66.  Thomas BE, Thiruvengadam K, Vedhachalam C, A S, Rao VG, Vijayachari P, et al. Prevalence of pulmonary tuberculosis among the tribal populations in India. PloS one. 2021;16(6):e0251519 (IF: 3.24) .

67.  Tiburcio R, Duarte BB, Narendran G, Queiroz ATLD, Selvaraj A, Nayak K, et al. Dynamics of T-lymphocyte activation related to paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in persons with advanced HIV. Frontiers in Immunology.12:4214 (IF: 7.561) .

68.  Vasantha M, Muniyandi M, Ponnuraja C, Srinivasan R, Venkatesan P. Bayesian structural equation modeling for post treatment health related quality of life among tuberculosis patients. PloS one. 2021;16(5):e0252205 (IF: 3.24) .

69.  Vivekanandan Kalaiselvan Shatrunajay Shukla, Kumar. SR, Mishra. N, Kumar. P, Raghuvanshi. RS. New Insights into the Future of Pharmacoepidemiology and Drug Safety (BOOK CHAPTER). BOOK. 2021.